Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06369727
Other study ID # MOB015B-VI
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date October 15, 2017
Est. completion date February 15, 2018

Study information

Verified date April 2024
Source Moberg Pharma AB
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A Randomized, Controlled Study to Evaluate the Sensitizing Potential of MOB015B in Healthy Subjects Using a Repeat Insult Patch Test Design To evaluate the sensitization potential


Description:

MOB015B is a topical solution for the treatment of nail fungus (onychomycosis) containing the active antifungal ingredient terbinafine. Terbinafine is a well-known antifungal agent that has been widely used for decades for both in topical and oral preparations and is regarded as an effective treatment of dermatophyte infections. In a phase II study, MOB015B was found to be efficacious and safe in the topical treatment of distal subungual onychomycosis. This Phase 1 study will assess the sensitization potential of MOB015B.


Recruitment information / eligibility

Status Completed
Enrollment 250
Est. completion date February 15, 2018
Est. primary completion date February 15, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Is a healthy male or female (to be confirmed by medical history); 2. Is 18 years of age or older; 3. In the case of a female of childbearing potential, is using an acceptable form of birth control (oral/implant/injectable/transdermal contraceptives, intrauterine device, condom with spermicide, diaphragm with spermicide, abstinence, partner's vasectomy, tubal ligation). Abstinence or vasectomies are acceptable if the female subject agrees to implement one of the other acceptable methods of birth control if her lifestyle/partner changes; 4. In the case of a female of childbearing potential, has a negative urine pregnancy test (UPT) on Day 1 prior to randomization and are willing to submit to a UPT at the end of study (EOS); 5. Is free of any systemic or dermatological disorder, which, in the opinion of the Investigator, will interfere with the study results or increase the risk of AEs; 6. Is of any Fitzpatrick Skin Type or race, providing the skin pigmentation will allow discernment of erythema (see Table 1); 7. Complete a medical screening procedure; and 8. Read, understand, and sign an informed consent. Exclusion Criteria: 1. Has any visible skin disease at the application site which, in the opinion of the Investigator, will interfere with the evaluation of the test site reaction; 2. Is using systemic/topical corticosteroids within 3 weeks prior to and/or during the study, or systemic/topical antihistamines 72 hours prior to and during the study; 3. Is not willing to refrain from using systemic/topical anti-inflammatory analgesics such as aspirin (81 mg daily aspirin will be allowed), Aleve, Motrin, Advil, or Nuprin for 72 hours prior to and during the study (occasional use of acetaminophen will be permitted); 4. Is using medication which, in the opinion of the Investigator, will interfere with the study results (e.g. anti-inflammatory medications, antipsychotics, anticonvulsants with potential pain relief effects, immunomodulatory medications, and others); 5. Is unwilling or unable to refrain from the use of sunscreens, cosmetics, creams, ointments, lotions or similar products on the back during the study; 6. Has psoriasis and/or active atopic dermatitis/eczema; 7. Has a known sensitivity or allergy to constituents of the materials being evaluated; 8. Is a female who is pregnant, plan to become pregnant during the study, or is breast feeding a child; 9. Has damaged skin in or around the test sites, including sunburn, excessively deep tans, uneven skin tones, tattoos, scars, excessive hair, numerous freckles, or other disfigurations of the test site; 10. Has received treatment for any type of internal cancer within 5 years prior to study entry; 11. Has a history of, or are currently being treated for skin cancer and/or hepatitis; 12. Has a history of, or is currently being treated for, insulin dependent diabetes; 13. Has any condition that might compromise study results; 14. Currently or expect to sunbathe or use tanning salons during the study; 15. Is currently participating in any clinical testing; 16. Has any known sensitivity to adhesives; and/or 17. Has received any investigational drug(s) within 4 weeks prior to study entry.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
MOB015B
Topcal formulation
MOB015B vehicle
Topcal formulation
Negative irritant solution of 0.9% saline
Negative control

Locations

Country Name City State
United States TKL Research, Inc Fair Lawn New Jersey

Sponsors (1)

Lead Sponsor Collaborator
Moberg Pharma AB

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary To determine the potential of MOB015B to induce sensitization by repeated topical application to the healthy skin of humans under controlled conditions. Evaluation of dermal reactions at the application sites assessed clinically using a visual scale that rates the degree of erythema, edema, and other signs of cutaneous irritation. 6 weeks
Primary To assess safety Evaluation of any adverse events (AEs) reported during the study.application to the healthy skin of humans. 6 weeks
See also
  Status Clinical Trial Phase
Withdrawn NCT04290273 - Characterisation of the Time-course Response of UV-induced Erythema N/A
Completed NCT01659853 - Efficacy and Safety Study Comparing CD07805/47 Gel 0.5% to Azelaic Acid Gel 15% in Subjects With Erythema of Rosacea Phase 3
Completed NCT00839462 - Efficacy of Dexpanthenol in Thermic Erythema Phase 2
Not yet recruiting NCT06016361 - Evaluation of a Novel Amino Acid Based Moisturizing Cream as Part of the Daily Standard Skincare Regimen Recommended During Radiation Therapy N/A
Completed NCT03633877 - Durapore vs. Hy-Tape to Secure The Endotracheal Tube N/A
Active, not recruiting NCT02876107 - Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer Phase 2
Completed NCT06369675 - Skin Irritation Potential of MOB015B in Healthy Subjects Using a Cumulative Irritant Patch Test Design Phase 1
Completed NCT03352323 - An Evaluation of the Reduction in Erythema in Adult Patients With Moderate to Severe Persistent Facial Erythema Associated With Rosacea Phase 3
Completed NCT03041064 - Multiday Beach Study N/A
Completed NCT02832141 - Effect of Thoracic Spine Mobilization on Sympathetic Nervous Systems
Completed NCT02131636 - Efficacy and Safety of AGN-199201 in Patients With Persistent Erythema Associated With Rosacea Phase 3
Completed NCT01636765 - Study of Inter- and Intra-rater Reliability of the Clinician Erythema Assessment Scale
Terminated NCT01597921 - A DB Randomized Study of R1 and R2 WaterJel / AloeVera Jell in Prevention of Radiation Dermatitis in Breast Cancer N/A
Completed NCT01124513 - Melanin Index in Those With Fitzpatrick Skin Phototypes I-VI N/A
Terminated NCT03496584 - Effects of Phytonutrients on Vascular Health and Skin in Obese Males N/A
Completed NCT02737592 - A Clinical Study to Evaluate the Safety of a Personal Lubricant in Healthy Female Subjects N/A
Completed NCT03852563 - A Study to Gain Information How Well Dexpanthenol Derma Cream Helps the Face Skin to Recover After Cosmetic Lasering N/A
Completed NCT05300542 - Efficacy Study of a Novel Skin Health Product to Reduce an UVB Induced Erythema N/A
Completed NCT03477825 - Pilot Study of Triphala and Rubia Cordifolia on Gut Microbiome and Skin N/A
Completed NCT02490943 - A Pilot Study of Warm and Cold Compress to Reduce Injection Site Erythema Due to Peginterferon-beta-1a in MS N/A